Next Century Growth Investors Llc Trimmed Axogen Inc (NASDAQ:AXGN) Position by $11.31 Million; Price Rose

May 17, 2018 - By Benjamin Allen

AxoGen, Inc. (NASDAQ:AXGN) Corporate Logo

In Axogen Inc (NASDAQ:AXGN) was reduced the holdings owned by Next Century Growth Investors Llc. The reduction is 47.07% according to 2018Q1 Securities and Exchange form. 314,239 shares were sold by Next Century Growth Investors Llc as the company’s stock rose 43.24% while stock markets declined. At the end of 2018Q1, the 353,403 shares of the health care company held by the institutional investor were valued at $12.90M, down from 667,642 at the end of the previous reported quarter. For a total of shares it increased its holding in by shares in the quarter, and has risen its stake in .

Next Century Growth Investors Llc is a Minnesota-based institutional investor with more than $3.86 billion AUM in March, 2014. Taken from Next Century Growth Investors latest Adv, the fund reported to have 10 full and part-time employees. Among which 6 performing investment advisory and research functions. The institutional investor had between 26-100 clients.

AxoGen, Inc. (NASDAQ:AXGN) Ratings Coverage

A total of 7 analysts rate AxoGen (NASDAQ:AXGN) as follows: 7 “Buy”, 0 “Hold” and 0 “Sell”. Тherefore 100% are bullish. (NASDAQ:AXGN) has 11 ratings reports on May 17, 2018 according to StockzIntelligence. On Tuesday, May 1 the firm has “Market Outperform” rating given by JMP Securities. On Tuesday, November 21 the rating was maintained by Wedbush with “Buy”. On Monday, January 8 the rating was maintained by Cantor Fitzgerald with “Buy”. The company rating was maintained by Lake Street on Friday, March 2. On Tuesday, May 1 Cantor Fitzgerald maintained the shares of AXGN in report with “Overweight” rating. On Thursday, March 1 the rating was maintained by JMP Securities with “Market Outperform”. On Wednesday, February 28 Cantor Fitzgerald maintained AxoGen, Inc. (NASDAQ:AXGN) rating. Cantor Fitzgerald has “Buy” rating and $37.0 target. The stock rating was maintained by Leerink Swann with “Outperform” on Tuesday, November 21.

AxoGen, Inc. provides surgical solutions for peripheral nerve injuries.The firm is worth $1.66 billion. The companyÂ’s surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.Last it reported negative earnings. The Company’s solutions also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that is used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed.

AxoGen, Inc. (NASDAQ:AXGN) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: